Multiple myeloma (MM) with deletion of 13q13 is characterized by increased bone marrow (BM) neovascularization - Implications for treatment of high-risk disease.

Johannes Drach(Vienna General Hospital), Heidemarie Huber, H Gisslinger, Robert Königsberg(Kaiser-Franz-Josef-Spital), Eleonora Urbauer(University of Vienna), Klaus Geißler(University of Vienna), Katrin Fuchs(University of Geneva), S Schreiber(Christian-Albrechts-Universität zu Kiel), J Ackermann, Andreas Obermair(Royal Brisbane and Women's Hospital), Andreas Chott(University of Vienna), H. Kaufmann
Queensland's institutional digital repository (The University of Queensland)
November 1, 1999
Cited by 0

Related Papers

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
|The Lancet|2015|779
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
|Blood|2000|322
Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy
|Blood|1998|321
Cytotoxic/natural killer cell cutaneous lymphomas
|Cancer|2003|273